Literature DB >> 27526293

Histologic Spectrum of Giant Cell Tumor (GCT) of Bone in Patients 18 Years of Age and Below: A Study of 63 Patients.

Alyaa Al-Ibraheemi1, Carrie Y Inwards, Riyam T Zreik, Doris E Wenger, Sarah M Jenkins, Jodi M Carter, Jennifer M Boland, Peter S Rose, Long Jin, Andre M Oliveira, Karen J Fritchie.   

Abstract

Although the majority of giant cell tumors (GCTs) of the bone occur in adult patients, occasionally they arise in the pediatric population. In this setting they may be mistaken for tumors more commonly seen in this age group, including osteosarcoma, aneurysmal bone cyst, and chondroblastoma. All cases of primary GCT of the bone arising in patients 18 years and below were retrieved from our institutional archives and examined with emphasis on the evaluation of various morphologic patterns. Clinical/radiologic records were reviewed when available. Analysis for H3F3A/H3F3B mutations was performed in a subset of cases. Sixty-three (of 710) patients treated at our institution for GCT were 18 years of age and below. The following morphologic patterns were identified: fibrosis (31 cases, 49%), reactive-appearing bone (26, 41%), cystic change (7, 11%), foamy histiocytes (6, 10%), secondary aneurysmal bone cyst (3, 5%), and cartilage (2, 3%). Infarct-like necrosis was present in 17 tumors (27%), and the mitotic rate ranged from 0 to 35 mitoses/10 high-power fields (median 5 mitoses/10 high-power field). Follow-up information (n=55; 6 mo to 69.6 y; median, 11.6 y) showed 21 patients with local recurrence (38%) and 2 patients with lung metastasis (4%). Polymerase chain reaction with sequencing showed that 5 of 5 tested cases harbored H3F3A mutations. In summary, GCT arising in the pediatric population is rare, representing 9% of GCTs seen at our institution. The morphologic spectrum of these tumors is broad and similar to that seen in patients above 18 years of age. It is important to recognize that matrix formation may be observed in GCT, including reactive-appearing bone and cartilage, as well as areas of fibrosis mimicking osteoid production, to avoid misclassification as osteosarcoma or other giant cell-rich lesions common in children.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27526293     DOI: 10.1097/PAS.0000000000000715

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  13 in total

1.  Giant cell tumor of soft tissue is genetically distinct from its bone counterpart.

Authors:  Jen-Chieh Lee; Cher-Wei Liang; Christopher Dm Fletcher
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

2.  CORR ® Tumor Board: What are the Functional Results, Complications, and Outcomes of Using a Custom Unipolar Wrist Hemiarthroplasty for Treatment of Grade III Giant Cell Tumors of the Distal Radius?

Authors:  Megan E Anderson; Jim S Wu; Sara O Vargas
Journal:  Clin Orthop Relat Res       Date:  2016-09-13       Impact factor: 4.176

Review 3.  [New aspects on giant cell tumor of bone].

Authors:  J Lüke; M Hasenfratz; P Möller; T F E Barth
Journal:  Pathologe       Date:  2018-03       Impact factor: 1.011

4.  Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy.

Authors:  Inga-Marie Schaefer; Jonathan A Fletcher; G Petur Nielsen; Angela R Shih; Marco L Ferrone; Jason L Hornick; Xiaohua Qian
Journal:  Cancer Cytopathol       Date:  2018-05-14       Impact factor: 5.284

5.  H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.

Authors:  Lihua Gong; Marilyn M Bui; Wen Zhang; Xiaoqi Sun; Ming Zhang; Ding Yi
Journal:  Histol Histopathol       Date:  2020-09-04       Impact factor: 2.303

Review 6.  Soft Tissue Special Issue: Giant Cell-Rich Lesions of the Head and Neck Region.

Authors:  Jen-Chieh Lee; Hsuan-Ying Huang
Journal:  Head Neck Pathol       Date:  2020-01-16

7.  H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone.

Authors:  Fernanda Amary; Fitim Berisha; Hongtao Ye; Manu Gupta; Alice Gutteridge; Daniel Baumhoer; Rebecca Gibbons; Roberto Tirabosco; Paul O'Donnell; Adrienne M Flanagan
Journal:  Am J Surg Pathol       Date:  2017-08       Impact factor: 6.394

8.  Preoperative CT for prediction of local recurrence after curettage of giant cell tumor of bone.

Authors:  Lenian Zhou; Shanyi Lin; Hanqiang Jin; Zhaoyuan Zhang; Changqing Zhang; Ting Yuan
Journal:  J Bone Oncol       Date:  2021-05-11       Impact factor: 4.072

Review 9.  Denosumab Treatment for Giant Cell Tumors, Aneurysmal Bone Cysts, and Fibrous Dysplasia-Risks and Benefits.

Authors:  Kristen S Pan; Alison M Boyce
Journal:  Curr Osteoporos Rep       Date:  2021-02-22       Impact factor: 5.163

Review 10.  Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation.

Authors:  Alison M Boyce; Michael T Collins
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.